

Resource Summary Report

Generated by [NIF](#) on Sep 15, 2026

KMS-34

RRID:CVCL_2996

Type: Cell Line

Proper Citation

RRID:CVCL_2996

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2996

Proper Citation: RRID:CVCL_2996

Description: Cell line KMS-34 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Plasma cell myeloma

Defining Citation: [PMID:15215163](#), [PMID:17171682](#), [PMID:17692805](#), [PMID:18647998](#), [PMID:18700954](#), [PMID:19306352](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:30285677](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:32123307](#)

Comments: Characteristics: Produces IgA kappa., Population: Japanese., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KMS-34

Synonyms: KMS34, Kawasaki Medical School-34

Cross References: EFO:EFO_0006619, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, BioSample:SAMN03472430, BioSample:SAMN03472927, BioSample:SAMN10987826, cancercellines:CVCL_2996, Cell_Model_Passport:SIDM01473, CGH-DB:26-1, CGH-DB:9139-4, Cosmic:2081395, Cosmic:2367284, Cosmic:2391796, DepMap:ACH-000541, EGA:EGAS00001000610, EGA:EGAS00001002554, GEO:GSM143332, GEO:GSM290301, GEO:GSM887228,

GEO:GSM888302, GEO:GSM1692596, GEO:GSM1692597, GEO:GSM1692598,
IARC_TP53:28382, JCRB:JCRB1195, LiGeA:CCLE_142,
PharmacDB:KMS34_772_2019, Progenetix:CVCL_2996, Wikidata:Q54900182

ID: CVCL_2996

Record Creation Time: 20220427T220706+0000

Record Last Update: 20260913T004701+0000

Ratings and Alerts

No rating or validation information has been found for KMS-34.

No alerts have been found for KMS-34.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Tiwari PK, et al. (2026) An orally active dual CBP/p300 degrader targets core dependencies of multiple myeloma. Cell reports, 45(6), 117464.

Ye T, et al. (2024) Identification of WNK1 as a therapeutic target to suppress IgH/MYC expression in multiple myeloma. Cell reports, 43(5), 114211.

Bolomsky A, et al. (2024) IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma. Cancer cell, 42(7), 1185.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Masuda T, et al. (2022) Identification of a drug-response gene in multiple myeloma through longitudinal single-cell transcriptome sequencing. iScience, 25(8), 104781.

Cottini F, et al. (2022) Redefining CD56 as a Biomarker and Therapeutic Target in Multiple Myeloma. Molecular cancer research : MCR, 20(7), 1083.

Vannam R, et al. (2021) Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. Cell chemical biology, 28(4), 503.